Replies to post #157605 on Biotech Values

[DewDiligence]

More color on MYL’s acquisition of Strides:

http://www.bloomberg.com/news/2013-02-27/mylan-to-buy-strides-injectables-unit-for-1-6-billion.html

Agila, based in Bangalore, had the highest number of injectable-medicine approvals by the FDA for generic drugs, with 32 from 2008 to 2010, compared with 23 at Hospira Inc. (HSP) of Lake Forest, Illinois, according to a May presentation. The company has eight manufacturing facilities in India, Brazil and Poland, according to its website.

The deal will boost Mylan’s portfolio of injectable drugs from 500 to 700, with another 350 awaiting approval around the world. The company projects the generic-drug market to grow at about 13 percent a year through 2017, and the deal will give it entry into new markets including Brazil.

In other words, this deal is largely about The Global Demographic Tailwind.

[DewDiligence]

MYL’s acquisition of Agila (#msg-85095031) may be in doubt:

http://online.wsj.com/article/SB10001424127887324139404579016782936626884.html

In July, the Indian government froze U.S. drug maker Mylan Inc.'s proposed $1.6 billion acquisition of Agila Specialties Pvt. Ltd., an Indian manufacturer of injectable cancer drugs. The government was concerned that these drugs would be exported to more lucrative markets abroad, reducing the domestic supply.

India's Prime Minister Manmohan Singh on Friday asked the Department of Industrial Policy and Promotion to suggest possible changes to investment regulations, a senior government official told The Wall Street Journal.